You must log in to view this page.

Adagene Inc. – Filings and Transcripts

NASDAQ: ADAG
Share price (3/24/26): $3.61
Market cap (3/24/26): $170 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 12/31/24 FY 2024

ended 12/31/23 FY 2023

ended 12/31/22 FY 2022

ended 12/31/21 FY 2021

ended 12/31/20 FY 2020

Prospectuses and Registrations Filter

Prospectus supplement

Shelf registration

Prospectus supplement for primary offering

Shelf registration – amended

Shelf registration

Ownership Filter

Chane-Du Mickael Yannick

News Filter

Provides Business Update and 2026 Objectives

Announces Licensing Agreement With Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Reports Six Months 2025 Financial Results and Provides Corporate Updates

- Alignment Gained on Phase 2 Inclusion/Exclusion Criteria, Primary and Secondary Endpoints, and Study Design, Including Sample Size and Dosing Regimen - Company Expects to Begin Enrolling Patients in Phase 2 in 2H 2025

Announces Up to $25 Million Strategic Investment From Sanofi

Proxies

No filings in this category.

Other Filter

Notice of effectiveness

Notice of effectiveness

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC